I work at a firm that specializes in emerging Chinese companies traded in the US on the OTCBB, AMEX, NASDAQ and NYSE exchanges. We are unique in that we specifically limit the number of clients we will represent at any given time and focus on those which we believe will outperform both from a business and stock perspective.
We currently represent China Yongxin Pharmaceuticals (CYXN), who you covered in your article, along with several other companies that are trading at significant discounts and are also experiencing robust growth on both the top and bottom line. I couldn’t agree with you more on your take with CYXN
Well Ted, CYXN has not had a PR in over 3 months and is barely trading. If this is an example of HC International's ability to "focus on those which we believe will outperform both from a business and stock perspective", I'm unimpressed.
